Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.

CONCLUSION: Combined inhibition of AXL and HDACs in DIPG cells results in a synergistic antitumor effect by reversing their mesenchymal, stem cell-like, therapy-resistant phenotype. As such, this treatment combination may serve as part of a future multimodal therapeutic strategy for DIPG.
PMID: 32165429 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 11, 2020 Category: Cancer & Oncology Authors: Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero-Carcaboso A, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL, Hull Tags: Clin Cancer Res Source Type: research